Identification and Evaluation of Possible Approaches to Addressing Nitrosamine Impurities in Drugs (U01)
Last verified by NonDilute: 2026-04-29. Official notice and agency instructions control.
If you have expertise in analytical chemistry or drug manufacturing and can propose scalable methods to detect or eliminate nitrosamines from pharmaceuticals, the FDA is funding this exact problem.
Report stale or inaccurate summary
What this is
This FDA-sponsored U01 award targets research into nitrosamine impurities—unintended chemical contaminants discovered in various drug products over the past several years. The funding seeks proposals that develop novel identification methods, evaluation frameworks, or mitigation strategies to address this pharmaceutical safety issue. This is ideal for researchers with pharmaceutical chemistry, analytical method development, or drug manufacturing expertise who can propose concrete approaches to reduce or eliminate nitrosamines from the drug supply.
Who can apply
Eligibility details are unspecified in the source material, but U01 awards typically support universities, research institutions, small businesses, and nonprofits. Applicants should have technical expertise in pharmaceutical chemistry, analytical sciences, or drug manufacturing; domestic organizations are generally preferred for FDA funding.
Topics: nitrosamine impurities · pharmaceutical contamination · drug safety · analytical chemistry · pharmaceutical manufacturing · FDA compliance
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.